 BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV, developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the Companys Annual General Meeting held today, including the election of three new directors to the Companys Board of Directors, namely, Dr. Yael Margolin, Mr. Adi Raviv, and Mr. Samuel Moed. 